Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center

BACKGROUND: The FDA initially approved pembrolizumab and nivolumab for doses based on patient weight, but subsequently amended approval to fixed doses. We estimated savings from novel dosing strategies based on real‐world patient data from a single cancer center. METHODS: We analyzed all outpatient...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Evan, Zhang, Jenny, Kim, Eun Jeong, Hwang, Grace, Chu, Gilbert, Bhatia, Shailender, Reddy, Sunil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064089/
https://www.ncbi.nlm.nih.gov/pubmed/31994335
http://dx.doi.org/10.1002/cam4.2888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064089/
https://www.ncbi.nlm.nih.gov/pubmed/31994335
http://dx.doi.org/10.1002/cam4.2888

Ejemplares similares